| Cartilage Defect |
Autologous Bone Marrow Stem Cell Therapy for Patients with Cartilage Defects
(HIRA Non-covered Code: BL6051FE) |
No. 2012-1
(No. 183) |
Tissue regeneration |
Patients with cartilage defects
1. Aged 15–50, Cartilage
injury due to trauma, etc.
(ICRS Grade 3–4),
3. Cartilage defect size: 2–10 cm² |
| Critical Limb Ischemia (CLI) |
Autologous Bone Marrow Stem Cell Transplantation
for Critical Limb Ischemia
(HIRA Non-covered Code: BL6050FE) |
No. 2013-35
(No. 274) |
Induction of
angiogenesis
to delay limb amputation, treat skin ulcers, and improve function |
Patients with Fontaine’s Stage III or IV critical limb ischemia (thromboangiitis obliterans, peripheral arterial occlusive disease) who have failed or are not
eligible for conventional treatments |
| Myocardial Infarction |
Autologous Bone Marrow Stem Cell Therapy for Myocardial Infarction Patients |
No. 2013-178
(No. 347) |
Improvement of cardiac function |
Patients with myocardial infarction
who show no improvement despite conventional treatments such as medication or coronary intervention |
| Knee Osteoarthritis |
Intra-articular Injection of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis |
No. 2023-128 |
Pain relief and functional improvement of the knee joint |
Patients with knee osteoarthritis classified as CRS Grade 3–4 (International Cartilage Regeneration & Joint Preservation Society) or KL Grade 2–3 (Kellgren–Lawrence) |
